Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan
· Delayed Price · Currency is TWD 48.00
+0.40 (0.84%)
Apr 29, 2026, 1:30 PM CST
Medigen Vaccine Biologics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 592.04 | 715.61 | 1,393 | 1,204 | 1,380 | Upgrade
|
| Short-Term Investments | 1,180 | 1,200 | 2,364 | 2,980 | 800 | Upgrade
|
| Trading Asset Securities | - | - | - | 52.99 | 53.1 | Upgrade
|
| Cash & Short-Term Investments | 1,772 | 1,916 | 3,757 | 4,237 | 2,233 | Upgrade
|
| Cash Growth | -7.50% | -49.02% | -11.33% | 89.77% | 28.87% | Upgrade
|
| Accounts Receivable | 130.02 | 118.03 | 149.11 | 194.4 | 640.19 | Upgrade
|
| Other Receivables | 12.52 | 9.98 | 49.74 | 1.17 | 0.07 | Upgrade
|
| Receivables | 142.54 | 128.01 | 198.84 | 195.57 | 640.26 | Upgrade
|
| Inventory | 393.75 | 452.06 | 383.64 | 903.4 | 610.84 | Upgrade
|
| Prepaid Expenses | 16.56 | 20.44 | 13.49 | 12.37 | 32.29 | Upgrade
|
| Other Current Assets | 37.87 | 40.79 | 48.14 | 113.89 | 205.07 | Upgrade
|
| Total Current Assets | 2,363 | 2,557 | 4,401 | 5,462 | 3,721 | Upgrade
|
| Property, Plant & Equipment | 1,244 | 1,354 | 1,385 | 1,470 | 1,414 | Upgrade
|
| Long-Term Investments | 287.97 | 407.99 | 246.13 | 263.56 | 54 | Upgrade
|
| Other Intangible Assets | 21.14 | 29.38 | 38.3 | 45.36 | 52.98 | Upgrade
|
| Other Long-Term Assets | 17.93 | 16.07 | 22.36 | 106.83 | 57.26 | Upgrade
|
| Total Assets | 3,934 | 4,364 | 6,093 | 7,348 | 5,299 | Upgrade
|
| Accounts Payable | 10.6 | 13.39 | 25.89 | 109.1 | 88.53 | Upgrade
|
| Current Portion of Long-Term Debt | - | 23.15 | 1,708 | - | - | Upgrade
|
| Current Portion of Leases | 13.84 | 16.11 | 12 | 11.78 | 1.99 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 111.41 | Upgrade
|
| Other Current Liabilities | 160.61 | 161.57 | 245.73 | 234.35 | 237.15 | Upgrade
|
| Total Current Liabilities | 185.05 | 214.22 | 1,992 | 355.23 | 439.09 | Upgrade
|
| Long-Term Debt | - | - | - | 1,678 | - | Upgrade
|
| Long-Term Leases | 269.6 | 299.7 | 254.36 | 266.35 | 183.87 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 19.25 | - | Upgrade
|
| Total Liabilities | 454.64 | 513.92 | 2,246 | 2,319 | 622.95 | Upgrade
|
| Common Stock | 3,287 | 3,287 | 3,286 | 3,278 | 2,129 | Upgrade
|
| Additional Paid-In Capital | 357.92 | 407.38 | 1,551 | 2,798 | 1,135 | Upgrade
|
| Retained Earnings | -140.23 | 61.02 | -1,018 | -1,132 | 1,410 | Upgrade
|
| Comprehensive Income & Other | -25.92 | 94.25 | 27.85 | 84.03 | 1.92 | Upgrade
|
| Shareholders' Equity | 3,479 | 3,850 | 3,847 | 5,029 | 4,676 | Upgrade
|
| Total Liabilities & Equity | 3,934 | 4,364 | 6,093 | 7,348 | 5,299 | Upgrade
|
| Total Debt | 283.44 | 338.96 | 1,974 | 1,956 | 185.85 | Upgrade
|
| Net Cash (Debt) | 1,489 | 1,577 | 1,783 | 2,281 | 2,047 | Upgrade
|
| Net Cash Growth | -5.58% | -11.56% | -21.85% | 11.45% | 32.50% | Upgrade
|
| Net Cash Per Share | 4.53 | 4.80 | 5.43 | 7.05 | 6.37 | Upgrade
|
| Filing Date Shares Outstanding | 328.75 | 328.73 | 328.61 | 327.84 | 315.67 | Upgrade
|
| Total Common Shares Outstanding | 328.75 | 328.73 | 328.61 | 327.84 | 315.67 | Upgrade
|
| Working Capital | 2,178 | 2,343 | 2,410 | 5,107 | 3,282 | Upgrade
|
| Book Value Per Share | 10.58 | 11.71 | 11.71 | 15.34 | 14.81 | Upgrade
|
| Tangible Book Value | 3,458 | 3,821 | 3,808 | 4,984 | 4,623 | Upgrade
|
| Tangible Book Value Per Share | 10.52 | 11.62 | 11.59 | 15.20 | 14.65 | Upgrade
|
| Buildings | 1,141 | 1,133 | 1,130 | 1,127 | 1,121 | Upgrade
|
| Machinery | 697.26 | 686.4 | 650.64 | 626.59 | 570.9 | Upgrade
|
| Construction In Progress | - | 2.57 | 21.37 | 14.54 | 4.7 | Upgrade
|
| Leasehold Improvements | 9.41 | 9.35 | 3.34 | 3.03 | 2.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.